Hepatitis B Topics HBV Disease Progression Decompensation & ESLD
Liver Disease Is Leading Cause of Death for People with Chronic Hepatitis B
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 15 January 2013 00:00
- Written by Liz Highleyman
Advanced liver disease caused by hepatitis B virus (HBV) -- including hepatocellular carcinoma (HCC) and decompensated cirrhosis -- accounted for more than 40% of deaths of people with chronic hepatitis B in a large health maintenance organization, researchers reported in the December 12, 2012, advance online edition of Hepatology.
Antiviral Therapy Safe and Effective for Hep B Patients with Advanced Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Antiviral drugs including entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and tenofovir (Viread) are generally well-tolerated and effective against hepatitis B virus (HBV) in people with liver cirrhosis, and may lower mortality even among patients with severe decompensated cirrhosis, according to 2 recently published studies.
Tenofovir Improves Outcomes of HBV Acute-on-Chronic Liver Failure
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 10 May 2011 09:06
- Written by Liz Highleyman
Treatment with tenofovir (Viread) lowers HBV viral load, reduces liver injury, and decreases the risk of death in patients with acute-on-chronic liver failure due to hepatitis B reactivation. 
Entecavir vs Adefovir in Hepatitis B Patients with Liver Decompensation
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 26 July 2011 00:00
- Written by James Learned
In a head-to-head comparison, entecavir (Baraclude) demonstrated superior virological efficacy compared to adefovir (Hepsera) in hepatitis B patients with decompensated liver disease.
Web Design and Development by